FIGURE

Fig. 3

ID

ZDB-FIG-140214-3

Publication

Jacob et al., 2014 - Valproic Acid silencing of ascl1b/ascl1 results in the failure of serotonergic differentiation in a zebrafish model of Fetal Valproate Syndrome

Other Figures

All Figure Page

Back to All Figure Page

Fig. 3

VPA treatment exposes cryptic transcriptional repression of ascl1b by basal levels of Notch signalling. (A) Quantitative reverse-transcriptase PCR showing that VPA mildly reduces her4 expression, whereas DAPT strongly reduces her4 expression to between 12% and 23% of control levels (*P=0.017, **P=0.001). (B) Short duration (8 hour) treatment with VPA [condition (viii)] does not upregulate her4 expression at 32 hpf (n=12/12). Downregulation of her4 expression in hdac1^s436 mutant hindbrain at 32 hpf (n=5/5). Scale bar: 50 µm. (C) Concomitant blockade of Notch signalling using the γ-secretase inhibitor DAPT prevents the downregulation of ascl1b by VPA. Loss of her4 expression in DAPT-treated embryos [conditions (ix) and (x)] (upper panels) (n=35/35). Persistence of ascl1b expression in embryos treated with VPA and DAPT [condition (x)] (n=23/23).

Expression Data

Genes:	ascl1b her4.1
Fish:	WT hdac1^s436/s436
Conditions:	chemical treatment: DAPT chemical treatment: DAPT chemical treatment: pharmaceutical
Anatomical Terms:	hindbrain rhombomere
Stage:	Prim-15

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Dis. Model. Mech.